IXICO PLC (LON:IXI), the brain imaging analytics specialist, has received a £2mln extension to a contract to provide additional imaging services for a pivotal Huntington's disease (HD) study.
The company, described a 'top-20' pharma client by IXICO is carrying out a Phase III study into a treatment for the disease.
IXICO added the contract will not have a significant performance for the coming year but will add to the company's order book for the year after.
Giulio Cerroni, IXICO’s chief executive, said: "We are delighted that our client has chosen to expand our partnership to support its study extension for Huntington's disease.
“This decision validates our technology and endorses the service provided as we help our clients throughout the trial pathway.”